Articles related to LEUKEMIA

The decision to remove Lumoxiti from the US market was attributable to its extremely poor clinical uptake because there were other treatment choices available, according to AstraZeneca’s letter to healthcare professionals. Its limited uptake may also have been caused by the complicated administration, the requirement for toxicity prophylaxis, and the need for safety monitoring. The elimination has nothing to do with the drug’s efficacy or safety.

Today, it is possible to safely treat CML throughout pregnancy with little danger to the unborn child, as TKIs can now be safely administered during the later stages of pregnancy, according to new research. After beginning or continuing TKI therapy, a sizable majority of patients can be managed by observation alone, and disease control can be attained. IFN-α may be given in any trimester with little harm to the fetus if active treatment is necessary. Most essential, however, is a multidisciplinary strategy to offer clear and concise guidance to enable both the mother and the family to participate in the decision-making process.

Data from Study 2102-HEM-101, an open-label, single-arm, multicenter phase 1/2 trial, were used to support the approval. The Abbott RealTime IDH1 Assay was used to identify 147 adults with relapsed or refractory AML who had an IHD1 mutation. Olutasidenib treatment resulted in a 35% complete remission (CR) or complete remission with partial hematologic recovery in patients (CRh).

Acute lymphoblastic leukemia (ALL) with Philadelphia chromosome positivity (Ph+) has a poor prognosis historically, so allogeneic hematopoietic cell transplantation (allo-HCT) is advised after the first complete remission (CR1). The rapid achievement of a complete molecular remission (CMR), however, is associated with excellent outcomes without allo-HCT in the tyrosine kinase inhibitor (TKI) era, indicating transplant may not be necessary for these patients. To test this theory, the authors of this journal-based CME program looked into 5 transplant centers in the US to find adult Ph+ ALL patients who received induction therapy, such as TKIs, and received CMR within 90 days of diagnosis. They then compared the outcomes of people who received allo-HCT in the first remission versus those who did not.

This study provides evidence that older patients with Binet stage A CLL, including those in the oldest age groups, can receive the Chronic Lymphocytic Leukemia International Prognostic Index (CLL-IPI). Because of the high median age in our study, we were also able to identify a relationship between del(17p) and age, which raises the possibility that age-adjusted prognostic tools could enhance CLL prediction. In cardiology, risk stratifications and recommendations for antilipid treatment have long taken into account the interaction between age and other risk factors for fatal cardiovascular disease, but in CLL, age is typically only considered as an additive factor in prognostic models.

The CRc rate was higher with GIL + AZA than with AZA in FLT3mut+ AML patients who were not suitable for intensive chemotherapy. In addition, OS did not differ significantly between GIL + AZA and AZA in FLT3mut+ AML patients who were not suitable for intensive chemotherapy.